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Abstract 26 
Based on the high expression of Carbonic Anhydrase IX (CAIX) in 95% of clear cell renal cell 27 
carcinoma (ccRCC), the anti-CAIX monoclonal antibody girentuximab can be used for the detection 28 
of ccRCC. This clinical study explores the value of 89Zr-labeled girentuximab PET/CT imaging in 29 
diagnostic challenges regarding ccRCC. PET/CT imaging was performed 4 or 5 days after injection of 30 
89Zr-girentuximab in patients with a primary renal mass (n=16) or a history of ccRCC (n=14). Scans 31 
were used for decision making (surgery/active surveillance) in case of indistinct renal masses. All 32 
resected PET-positive primary lesions proved to be ccRCC, while no lesion progression was seen in 33 
PET-negative masses. In patients suspected of recurrent/metastatic ccRCC, PET/CT with 89Zr-34 
girentuximab was useful to confirm or exclude ccRCC, to evaluate the extent of the disease and to 35 
differentiate from other cancers. In this group 89Zr-girentuximab PET/CT resulted in a major change in 36 
clinical management in five patients (36%), while in three patients (21%) repeat biopsies could be 37 
avoided. We conclude that 89Zr-girentuximab PET/CT is a valuable diagnostic tool that can guide 38 
clinical decision making in case of diagnostic dilemmas concerning ccRCC suspicion. 39 
Patient summary: 89Zr-girentuximab PET/CT imaging can be a valuable diagnostic tool to identify 40 
ccRCC. 41 
 42 
Non-invasive confirmation of the presence or absence of clear cell renal cell carcinoma 43 
(ccRCC) can be useful to guide clinical decision making in patients with indistinct primary 44 
renal tumors or patients suspected of recurrent or metastatic ccRCC. The high expression of 45 
Carbonic Anhydrase IX (CAIX) in 95% of ccRCC allows detection with the anti-CAIX 46 
monoclonal antibody girentuximab[1]. Multiple studies have confirmed the high accuracy of 47 
radionuclide imaging using radiolabeled girentuximab[2-4]. A PET-tracer, like 89Zr-48 
girentuximab, allows better contrast and spatial resolution compared to SPECT-tracers. 49 
Furthermore, animal studies have demonstrated that 89Zr-girentuximab outperforms 124I-50 
girentuximab in terms of tumor-to-normal tissue ratios[5, 6]. 51 
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This phase I/II study aims to evaluate the value of 89Zr-labeled girentuximab PET/CT 52 
imaging in 30 patients suspected of ccRCC in whom the clinician faced a diagnostic dilemma 53 
defined as doubt about the best medical treatment despite conventional diagnostics. Two 54 
subgroups were distinguished: 1. patients with an indistinct renal mass, and 2. patients 55 
suspected of recurrent/metastatic ccRCC. Whole body PET/CT images were obtained 4-5 56 
days after injection of 5mg 89Zr-girentuximab (37 MBq). Lesions of interest were considered 57 
PET-positive or PET-negative based on a visual scale taking into account the background 58 
signal in surrounding organs and blood. Patient management was discussed in a 59 
multidisciplinary meeting before and after PET/CT results. A major change in management 60 
was defined as a change in one of the next step strategies; surgery (including surgical 61 
strategy), surveillance, or systemic therapy. The study was approved by Regional Internal 62 
Review Board (clinicaltrials.gov; NCT02883153). All patients signed informed consent.  63 
In group 1 (n=16), 89Zr-girentuximab PET/CT imaging was used in the decision to 64 
either perform surgery or active surveillance. In all cases follow-up data supported the 65 
decision (Table S1). In six patients tumors were PET-positive and five of them underwent 66 
surgery confirming ccRCC (Fig. S1). In the sixth patient (Fig. S2), with Von Hippel Lindau 67 
(VHL) syndrome, PET/CT revealed additional PET-positive lesions compared to MRI and the 68 
largest lesion was treated by cryoablation for debulking purposes. In patient #12, active 69 
surveillance of a 0.9cm PET-positive (follow-up: stable disease) and a 4cm PET-negative 70 
lesion (follow-up: shrinking) was initiated due to extensive previous abdominal surgery. In 71 
nine patients tumors were PET-negative and they were followed by active surveillance. None 72 
of the PET-negative tumors progressed during follow-up (mean 13.0±4.9 months), and these 73 
lesions are considered most likely to be benign or indolent non-ccRCC. However, longer 74 
follow-up is needed since average growth of renal tumors is 3 mm/year[7].  75 
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The confirmation of the presence or absence of ccRCC by 89Zr-girentuxumab PET/CT 76 
imaging results provided valuable information for clinical decision making in challenging 77 
cases, such as patients with a relative contraindication for surgery. 89Zr-girentuximab is not 78 
nephrotoxic and can be used in patients with renal insufficiency. Due to the highly specific 79 
CAIX-targeting , 89Zr-girentuximab does not target other RCC subtypes. However, a negative 80 
89Zr-girentuximab PET/CT lowers the a priori chance of lesions with a high malignant 81 
potential, which also aids in clinical decision making.  82 
Group 2 contained fourteen patients suspected of recurrent or metastatic ccRCC (Table 83 
S2). In case of oligometastatic disease, surgery with curative intent can be considered, 84 
whereas in case of extensive metastatic disease, there are only systemic treatment options 85 
with a palliative effect. Confirmation of oligometastases prior to metastasectomy is of utmost 86 
importance to avoid futile surgery. Eight patients (#17 to #24) were considered for surgery 87 
with curative intent. In three of them high uptake in the lesion of interest was seen and 88 
surgery was performed confirming ccRCC (Fig. 1). In patient #17 surgery was performed 89 
despite a negative PET/CT due to a high clinical suspicion (CAIX-expressing papillary 90 
growing ccRCC, false negative PET/CT). In patient #22 surgery could be limited to an 91 
adrenalectomy, since the enlarged contralateral lymph node was PET-negative (follow-up: 92 
stable disease). In three patients (#19-20, #24) curative surgery was cancelled since PET/CT 93 
imaging revealed additional metastases or did not confirm ccRCC recurrence (Fig. 2).  94 
The remainder of the patients in group 2 had multiple suspicious lesions. Patients #25-95 
#26 were previously diagnosed with metastatic ccRCC and 89Zr-girentuximab PET/CT 96 
imaging was used to evaluate the extent of the disease. In patients #27–30 previous biopsies 97 
were inconclusive or considered to be too invasive to perform. The invasive nature can make 98 
a re-biopsy less desirable. In patients #27-29 multiple PET-positive lesions were visualized 99 
indicating metastatic ccRCC with follow-up indeed showing lesion progression (#27 lost to 100 
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follow-up). In patient #30 the pulmonary lesions were PET-negative. Under the suspicion of 101 
lung cancer, a lobectomy was performed that confirmed primary lung adenocarcinoma (Fig. 102 
S3). As 89Zr-girentuximab PET/CT visualizes the underlying tumor biology (CAIX 103 
expression), it can be used to distinguish ccRCC from other cancers, which is important since 104 
treatment strategies can be essentially different. Hypoxia-driven CAIX expression has been 105 
described in other malignancies, but the mutational loss of VHL in ccRCC leads to a much 106 
higher expression[1]. 107 
The impact on clinical management in group 1 was difficult to express objectively, 108 
since treatment of renal masses did not follow strict guidelines but was subject to preferences 109 
of both the clinician and the patient. In group 2, a major change in clinical management 110 
occurred in five patients (36%). In three patients (21%) repeated biopsies were avoided, since 111 
the 89Zr-girentuximab PET/CT was positive, highly suggestive for ccRCC. Clinical 112 
management was never changed solely on 89Zr-girentuximab PET/CT imaging results, but 113 
with all clinical data taken into consideration. In the remainder of the patients PET/CT 114 
imaging confirmed clinical practice, but provided more certainty to decide on clinical 115 
management.  116 
The aim of the current study, to evaluate the value of 89Zr-girentuximab PET/CT 117 
imaging in diagnostic challenges, led to the inclusion of a heterogeneous study population, 118 
which can be considered a limitation of this study. Furthermore, the absence of 119 
histopathological confirmation in some patients precludes adequate calculation of diagnostic 120 
accuracy. A large phase III trial will be initiated. 121 
In conclusion, this study shows the diagnostic value of 89Zr-girentuximab PET/CT for 122 
the detection of primary, recurrent or metastatic ccRCC. It may guide clinical decision 123 
making in case of  diagnostic dilemmas concerning ccRCC suspicion.  124 
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Figures 155 
 156 
Figure 1: Patient #18 presented with a suspicious lesion in the inferior caval vein (VCI 10 mm) 6 months after 157 
nephrectomy (pT3a ccRCC with a positive surgical margin at the renal vein). CT and multiparametric MRI (A) 158 
could not distinguish with certainty between tumor thrombus and a blood clot, and furthermore mpMRI revealed 159 
several enlarged lymph nodes (B, short axis up to 12 mm) and a liver lesion (C, 7 mm). 89Zr-girentuximab 160 
PET/CT imaging showed uptake of 89Zr-girentuximab in the inferior caval vein (D) thereby non-invasively 161 
confirming the presence of recurrent ccRCC. No uptake of  89Zr-girentuximab in the lymph nodes (E) nor the 162 
liver lesion (F) was seen, making ccRCC metastases less likely. Surgery was performed with resection of the 163 
lesion in the IVC (ccRCC) and several enlarged lymph nodes (benign). No change of the liver lesion was seen 164 
over 15 months. The value of the 89Zr-girentuximab PET/CT was to confirm the local recurrence, and, prior to 165 
metastasectomy, provide more certainty about the enlarged lymph nodes and the liver lesion. 166 
  167 
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   169 
Figure 2: Patient #20 underwent a radical nephrectomy for ccRCC six years earlier and now presented with a 170 
new renal tumor and a solitary adrenal metastasis on CT-thorax/abdomen(A). Prior to metastasectomy (radical 171 
nephrectomy + adrenalectomy), 89Zr-girentuximab PET/CT imaging was performed to confirm the diagnosis and 172 
to exclude other metastatic sites. Uptake of 89Zr-girentuximab in the primary renal mass and the adrenal lesion 173 
was seen (B), but also in the proximal radius (insert). The proximal radius was not in the field of view of the 174 
initial conventional imaging (CT-thorax/abdomen). Biopsy of the radius confirmed ccRCC metastasis which was 175 
treated with radiotherapy. If the bone lesion had not been detected, the patient would have undergone a radical 176 
nephrectomy and as a result would have been dependent on dialysis. This would have been futile surgery and a 177 
major decrease in quality of life.     178 
 179 
  180 
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Supplemental tables and figures 181 
Table S1: 89Zr-girentuximab PET/CT imaging in patients with renal masses 182 
# Age Dilemma/contra-indication to 
surgery 
Lesion of interest Size 
(cm) 
PET  Action after 
PET/CT 
Follow-up/ histology 
1 76 Mono-kidney Bosniak 3 2.6 + PN ccRCC 
2 63 Mono-kidney Bosniak 3 4.9 - FU SD 
3 76 Multifocal disease, comorbidity 8 solid tumors, 
bilateral 
1.5-
9.5 
- Biopsy/FU Oncocytoma 
4 49 Multifocal disease,  VHL 
syndrome  
(Fig S2) 
Bosniak 3 
Bosniak 3** 
Myelum (L5) 
Epididymis 
Cerebellum 
2 
1.32 
1.2 
< 1.0 
<1.0 
+ 
+ 
+ 
+ 
+ 
Cryoablation 
FU 
Biopsy inconclusive 
SD 
Hemangioblastoma 
Cystadenoma 
Hemangioblastoma 
5 29 Multifocal disease, biopsy 
inconclusive DD 
angiomyolipoma. 
Solid 
Solid 
3.5 
5.3 
- 
- 
FU 
FU 
SD 
SD 
6 66 Multifocal disease,  
DD with metastases of other 
malignancies* 
Solid 
Solid 
1.2 
2.2 
 
- 
- 
FU 
FU 
SD 
SD 
7 64 DD with metastasis of other 
malignancies (Synchronous lung 
carcinoma) 
Bosniak 3-4 3 + PN ccRCC 
8 50 Central lesion, PNx not feasible Bosniak 3 5.5 - FU SD 
9 47 Central lesion, PNx not feasible 
(Fig S4) 
Bosniak 3-4 2.8 - FU SD 
10 59 Central lesion, PNx not feasible Bosniak 3 1.1 - FU SD 
11 66 Extensive previous abdominal 
surgery (Fig S1) 
Bosniak 3 4.2 + RN ccRCC 
12 49 Extensive previous abdominal 
surgery 
Bosniak 3-4 
Solid (Contralateral 
kidney) 
4 
0.9 
- 
+ 
FU Shrinking 
SD 
13 70 Comorbidity Bosniak 3 2.7 + PN ccRCC 
14 63 Comorbidity Bosniak 3 9 - FU SD 
15 65 Other; metastases? Bosniak 3 
Adrenal  
3.7 
3.7 
+ 
- 
PN  
LA 
ccRCC 
Adrenal adenoma 
16 45 Other; Changing cystic lesion 
after marsupialisation; cystic 
ccRCC? 
Bosniak 3 10 - Marsupialisation 
because of 
symptomatic cyst 
No malignancy  
* History of colorectal carcinoma, prostate cancer and urothelial cell carcinoma. Metastases unlikely due to low tumor markers. Patient 183 
refused biopsy. ** PET/CT imaging revealed accumulation of 89Zr-girentuximab in multiple cystic lesions. Based on the PET/CT a bilateral 184 
radical nephrectomy was advised.  PN: partial nephrectomy; RN: radical nephrectomy; LA: laparoscopic adrenalectomy; FU: follow-up; SD: 185 
stable disease.  186 
 187 
  188 
11 
 
Table S2: The value of 89Zr-girentuximab PET/CT in patients with a history of ccRCC 189 
# Age Dilemma Hypothetical step Action after PET/CT Lesions Size (cm) PET  Histology/FU Comment 
17 47 Screening prior to 
metastasectomy 
Metastasectomy Metastasectomy Lymph node  1.4 - Papillary ccRCC False negative PET/CT 
18 67 Screening prior to 
metastasectomy 
(Fig 1) 
Metastasectomy Metastasectomy Thrombus ICV 
Lymph node 
Liver  
1.0 
1.2 
0.7 
+ 
- 
- 
ccRCC 
Benign 
SD 
Kidney recurrence 15 months after PET. 
19 68 Screening prior to 
metastasectomy 
 
Metastasectomy Consider metastatic ccRCC Lymp node (para-
aortal) 
Lymph node 
(Retroaortal) Muscle 
(iliac spine) 
1.8-2.6 
<1.0 
1.3 
+ 
+ 
+ 
PD 
PD 
PD 
 
20 52 Screening prior to 
metastasectomy 
(Fig 2) 
RN + LA Radiotherapy bone Kidney  
Adrenal  
Bone (Proximal 
radius) 
Myelum (L4) 
4.1 
4.1 
2.9 
 
0.9 
+ 
+ 
+ 
 
+/- 
ccRCC 
ccRCC 
ccRCC 
 
PD 
After a stable interval, surgery of the 
kidney and adrenal were performed. 
21 48 Screening prior to 
metastasectomy 
Metastasectomy Metastasectomy Pancreas tail 
Pancreas head 
Liver 
1.7 
0.5 
ns 
+ 
- 
+/- 
ccRCC 
ccRCC 
SD 
No liver lesion visualized with 
intraoperative ultrasound. Follow-up 
suggested an adrenal metastasis. 
22 52 Screening prior to 
metastasectomy 
Metastasectomy (adrenal 
+ contralateral LN) 
Metastasectomy (adrenal) Adrenal  
LN 
3.3 
1.5 
+ 
- 
ccRCC 
SD 
 
23 66 Screening prior to RN 
after PN 
RN + LA RN + LA Kidney  
Adrenal 
1.2 
1.2 
+ 
+/- 
ccRCC 
Adenoma 
 
24 57 Screening prior to RN 
after PN 
RN Follow-up Kidney 2.3 - SD  
25 60 Evaluate extent of the 
disease 
Consider metastatic ccRCC Maximize treatment Th7 
Gastroscopy 
Bone (Th7) 
Muscle 
Stomach 
1.3 
ns 
ns 
+ 
- 
+ 
ccRCC 
SD 
Benign 
 
26 58 Evaluate extent of the 
disease 
Consider metastatic ccRCC Cryoablation kidney for local 
control 
MRI vertebra. 
Kidney  
Thrombus ICV 
Lung 
Bone (C4) 
3.0 
1.9 
1.2 
ns 
+ 
- 
- 
+ 
ccRCC 
Shrinking  
Shrinking 
MRI: inflammation 
Multiple new pulmonary lesions six 
months after PET 
27 69 Biopsy inconclusive Biopsy Consider metastatic ccRCC Liver 
Lung 
Pancreas 
Adrenal 
Kidney 
Subcutis 
Liver 
9.0 
< 2.9 
1.6-2.4 
1.0 
1.4-3.1 
ns 
0.9-1.5 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
- Lost to follow-up 
28 73 Biopsy inconclusive Biopsy Consider metastatic ccRCC  Liver  
Pancreas 
Bone (Th6) 
Thyroïd 
1.8 – 10 
3.0 
ns 
2.7 
+ 
+ 
+ 
+ 
Overall PD  
29 70 Biopsy challenging 
due to tumor location 
Biopsy Consider metastatic ccRCC Lung  
Bone (Clavicula) 
0.6-2.3 
ns 
5.0 
15.6 
PD 
SD 
 
30 72 Biopsy challenging 
due to tumor location: 
Biopsy/Consider 
metastatic ccRCC 
Lobectomy Lung (multiple) 
 
0.8-1.9 - Primary lung carcinoma 
and granulomas 
 
12 
 
DD m+ ccRCC or 
primary lung 
carcinoma 
(Fig S3) 
In Bold are patients in whom 89Zr-girentuximab PET/CT imaging was considered to have a major impact on clinical management. In italic are additional lesions visualized due to 89Zr-girentuximab PET/CT imaging. 190 
+/- Inconclusive lesion on 89Zr-girentuximab PET/CT imaging due to small lesion size, slightly enhanced uptake and/or absence of a substrate on conventional imaging.   191 
PN: partial nephrectomy, RN: radical nephrectomy. LA: laparoscopic adrenalectomy. DD: differential diagnosis. SD: stable disease. PD: progressive disease. LN: lymph node. I.C.V.: inferior caval vein. Ns: no 192 
substrate on anatomical imaging. Consider metastatic ccRCC: in general this meant follow-up until progression of disease and then start systemic therapy.  193 
 194 
 195 
 196 
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 197 
 198 
Figure S1: A. Patient #11 was referred with a complex cystic renal mass in a pelvic kidney on MRI. Because of 199 
a glomerular filtration rate of 25 ml/min and extensive previous abdominal operations, the clinician preferred to 200 
obtain certainty about the presence of ccRCC. B. 89Zr-girentuximab PET/CT imaging visualized uptake of 89Zr-201 
girentuximab in the walls of the lesion and subsequent surgery confirmed the presence of ccRCC.   202 
 203 
 204 
Figure S2: Patient #4 was known to have Von Hippel Lindau syndrome and had several primary 205 
ccRCC in the past. On MRI (A, C) two suspicious growing lesions were visualized, but PET/CT 206 
imaging revealed multiple lesions with high accumulation of 89Zr-girentuximab (B, D). The largest 207 
renal lesion was treated by cryoablation, but unfortunately the biopsy that was retrieved during of the 208 
procedure was not representative. Focal uptake in the myelum on the level of the fifth lumbar vertebra, 209 
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the cerebellum and the epididymis was seen (E, circles), on conventional imaging matching with 210 
hemangioblastomas and cystadenomas respectively.  211 
 212 
213 
 Figure S3: Patient #28 had a history of ccRCC 16 years earlier (nephrectomy and immunotherapy because of 214 
pulmonary metastases, followed by a partial response). Small residual lesions remained stable over the past 215 
years, except for slowly growing pulmonary lesions in the left lower lobe of the long, which had a differential 216 
diagnosis of a primary lung carcinoma (A). PET/CT imaging demonstrated no uptake of 89Zr-girentuximab in the 217 
growing lung lesion, nor in the small residual lesions (B). Under the suspicion of a secondary primary lung 218 
cancer, a lobectomy was performed, confirming the presence of a primary lung carcinoma and several 219 
granulomas.  220 
 221 
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 222 
Fig S4: Patient #9 was diagnosed with a centrally located cystic lesion in the left kidney with thickened walls 223 
and enhancement of septa, classified as Bosniak 3-4 (CT; A coronal, C, transverse plane). Due to the central 224 
location of the tumor, a partial nephrectomy was considered not feasible. More certainty about the nature of the 225 
lesion prior to radical nephrectomy was desirable. Since the chance of malignancy was lowered due to the 226 
negative 89Zr-girentuximab PET/CT (B coronal, D transverse plane), active surveillance was advised. Neither 227 
growth nor progression of the lesion was seen during 12 months of follow-up.   228 
 229 
  230 
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Supplemental methods 231 
 232 
Patient population 233 
Two subgroups of patients were distinguished; 1. patients with a renal mass of unknown 234 
origin, and 2. patients with a history of ccRCC and a suspicion of recurrent or metastatic 235 
disease. All patients received at least one of the following conventional diagnostic modalities: 236 
contrast-enhanced CT, MRI and/or biopsy. Patients were over 18 years old and signed 237 
informed consent. Exclusion criteria were pregnancy or lactation and a history of a CAIX-238 
negative RCC. Lastly, patients that were on tyrosine kinase inhibitor (TKI) treatment within 239 
the last month were excluded, as treatment with TKI has demonstrated to decrease uptake of 240 
111In-girentuximab [8]. 241 
 242 
Preparation of 89Zr-girentuximab 243 
Conjugation of N-suc-desferal ester (VU Medical Center, Amsterdam, the Netherlands) to 244 
girentuximab (Wilex AG, Munich, Germany and Telix Pharmaceuticals, Melbourne, 245 
Australia) was performed as described previously [6]. At the day of injection 2 mg desferal-246 
girentuximab was radiolabeled with 37 MBq of Zirconium-89 (Perkin Elmer, The 247 
Netherlands).  The radiolabeling process was performed at a pH of 7.2. To achieve the desired 248 
pH value, oxalic acid, sodium carbonate and HEPES buffer (adjusted to pH 7.3 by use of 249 
sodium hydroxide solution) were added. After addition of 2 mg desferal-girentuximab and 250 
HEPES buffer, radiolabeling was allowed to take place during 60 minutes at room 251 
temperature. Next, unbound 89Zr was complexed by the chelator EDTA by incubation for 15 252 
minutes at room temperature. Then the product was purified using gelfiltration on disposable 253 
PD10 columns. To obtain a total protein dose of 5 mg, unlabeled girentuximab was added to 254 
lower undesired hepatic uptake of 89Zr-desferal-girentuximab. Radiochemical purity was 255 
17 
 
determined by high-performance liquid chromatography and exceeded 90%. The end product 256 
was diluted to a total volume of 10 ml with NaCl 0.9% and administered intravenously in ten 257 
minutes within 4 hours after radiolabeling. 258 
 259 
 260 
 261 
